Medical and cost burden of atherosclerosis among patients treated in routine clinical practice

Journal of Medical Economics

Volumn 13, Issue 3, 2010, Pages 500-507

  Ohsfeldt, Robert L ^a   Gandhi, Sanjay K ^b   Fox, Kathleen M ^c   Bullano, Michael F ^b   Davidson, Michael ^d  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Atherosclerosis; Cardiovascular events; Clinical practice; Costs

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL PRACTICE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; UNITED STATES;

AGED; ATHEROSCLEROSIS; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RETROSPECTIVE STUDIES; STROKE; UNITED STATES;

EID: 77956689201     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.506348     Document Type: Article

References (15)

1. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008;62:1246-1254
2. American Heart Association. Heart Disease and Stroke Statistics: 2007 Update. Dallas, TX. American Heart Association, 2007
3. Coronary Heart Statistics 2008: United Kingdom. Available at http://www.ws3.heartstats.web.baigent.net/datapage.asp?id=7998 [Accessed October 2009]
4. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383
5. Bakhai A. The burden of coronary, cerebrovascular and peripheral arterial disease. Pharmacoecon 2004;22(Suppl 4):11-18
6. Leys D. Atherothrombosis: a major health burden. Cerebrovasc Dis 2001; 11(Suppl 2):1-4
7. Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk from atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008;1:38-45
8. Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206
9. Gandra SR, Lawrence LW, Parasuraman BM, et al. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm 2006;12:546-554
10. Mody R, Kalsekar I, Kavookjian J, et al. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications 2007; 21:75-83
11. Blanchette CM, Gutierrez B, Ory C, et al. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008; 14:176-185
12. Harley C, Li H, Corey-Lisle P, et al. Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatr Epidemiol 2007;42:690-697
13. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-306
14. Margolis J, Barron JJ, Grochulski D. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm 2005; 11:727-734
15. Kiechl S, Willeit J, for the Bruneck Study Group. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 1999;19:1484-1490 (Pubitemid 29263018)